The Pap Test: Cervical Changes and Further Testing
Did you have a recent Pap smear that showed abnormal changes in the cells of your cervix or a positive HPV test and you need further testing? This article will help you understand the Pap and HPV test results and the most likely plan for follow up.
What is a Pap Test?
The Pap test, also called a "Pap smear" was introduced as a screening test for cervical cancer in 1943 by Dr. George Papanicolaou, for whom the test is named. The Pap test involves taking cells from the cervix, which is located at the top of the vagina, using a small brush or other tool. The sample is sent to a laboratory where it is examined for abnormal appearing cervical cells. A small percentage of abnormal cells can become cancer.
In many women, providers also use a test to detect Human Papilloma Virus (HPV) in conjunction with the pap test for cervical cancer screening. The large majority of cervical cancers are caused by certain "high-risk" strains of HPV. This test looks for these high-risk types of HPV in the cervical cells. This gives your provider more information about a possible cause of an abnormal pap result and helps to determine the next steps.
When should cervical cancer screening be done?
The American Cancer Society recommends the following guidelines for cervical cancer screening:
- All women should begin cervical cancer screening at age 25.
- Women between the ages of 25 and 65 should have:
- Primary HPV testing every 5 years. This test is not yet available at many centers/practices.
- If this test is not available, you should be screened with co-testing, which is a combination of an HPV and Pap test. This should be done every 5 years.
- If HPV testing is not available, then a Pap test alone should be performed every three years.
- Women over age 65 who have had regular cervical screenings that were normal should not be screened for cervical cancer.
- Women who have been diagnosed with cervical pre-cancer should continue to be screened until they meet one of the following criteria over the previous 10 years:
- Two negative, consecutive HPV tests.
- Or 2 negative, consecutive co-tests.
- Or 3 negative, consecutive pap tests in the last 3-5 years.
- Women who have had their uterus and cervix removed in a hysterectomy and have no history of cervical cancer or pre-cancer should not be screened.
- Women who have had the HPV vaccine should still follow the screening recommendations for their age group.
- While the ACS does not recommend cervical cancer screening every year, women should still see their provider for a well-woman checkup.
Women who are at high risk for cervical cancer may need to be screened more often. Women at high risk might include those with HIV infection, organ transplant, or in-utero exposure to the drug DES. They should talk with their doctor or nurse for specific recommendations.
How is the screening done?
During the gynecologic examination, a speculum is inserted into the vagina so that the cervix and vagina can be seen. The doctor or nurse inserts a cotton-tipped swab or small brush into the cervical opening (cervical os) to sample endocervical cells (which come from the area most at risk for cervical cancer).
Normal vaginal discharge contains cells that are shed from the cervix and uterus. Samples of these cells are taken for the Pap test. For this reason, you should not douche, have vaginal intercourse, use tampons or vaginal medication for 48 hours before the Pap test is done.
The samples are sent to a pathologist for detailed examination under a microscope. A report is sent to your doctor with a classification of the test results and a description of the cell changes. It can take up to three weeks to receive your results. An HPV test, looking for certain strains of the HPV virus associated with cervical cancer, can also be sent using the same sample.
Process of Cervical Changes
The cervix is the part of the uterus that extends into the vagina. There are two types of cells that line the cervix, one lines the outer cervix (portio) and another lines the inner cervix (endocervix). There is a distinct junction between the two cell types called the transformation zone. The Pap test is taken from this area because this where dysplasia (pre-cancer) and cancer most often arise.
Two common changes in cells are metaplasia and dysplasia.
Metaplasia - Metaplasia is generally described as a process of cell growth or cell repair that is benign (not cancerous). This process normally occurs in unborn babies, during adolescence, and with the first pregnancy. Studies have shown that metaplasia is present in more than one-half of all women at some point in their development. This is a normal finding and does not indicate cancer.
Dysplasia - In dysplasia, there is an increase in the number of cells formed, which do not mature as expected. This changes the inside of the cell. The higher the grade of dysplasia found on the cervix, the more likely that it will progress to invasive cancer. For this reason, dysplasia is thought of as a "pre-cancerous" condition. Dysplasias are almost always curable if managed appropriately. Although some mild dysplasias (LSIL) will regress without treatment, it is not possible to distinguish between dysplastic areas of the cervix that will return to normal and dysplastic areas which will progress and ultimately become cancer. In turn, these results require further testing.
Causes of Cervical Cell Changes
Inflammation often results in a mildly abnormal Pap test, resulting in the diagnosis of ASCUS in the Bethesda System or changes consistent with Human Papilloma Virus (HPV) infection. An inflamed cervix may appear red, irritated, or eroded. Some of the common causes of cervical inflammation are:
- Bacteria (from an infection).
- Viruses, especially herpes infections and condyloma cuminata (warts).
- Yeast or monilia infections.
- Trichomonas infections.
- Pregnancy, miscarriage, or abortion.
- Chemicals (for example, medications).
- Hormonal changes.
When the inflammation is treated, repair of the tissues through metaplasia usually will follow. In several months, a repeat Pap test will often then be normal.
Classification of Squamous Cells on the Pap Test
Several different classification schemes have evolved over the years for characterizing Pap test results. Unfortunately, this is a continuing source of confusion. The most commonly used classification scheme is the Bethesda System.
- ASC - atypical squamous cells. This is the most common abnormal finding in Pap tests. The Bethesda System divides this category into two groups:
- ASC-US - atypical squamous cells of undetermined significance. The squamous cells do not appear completely normal, but doctors are uncertain about what the cell changes mean. Sometimes the changes are related to HPV infection, but they can also be caused by other factors such as pregnancy. For women who have ASC-US, her cells may then be tested for the presence of high-risk HPV. If HPV is present, colposcopy (see below) will usually be done. Alternatively, the pap test may be repeated in 6 months, and if normal, she may resume the usual schedule of screening. If a woman has ASC-US on her pap with a negative test for high-risk subtypes of HPV, a pap and HPV test may just be repeated in one year without further testing.
- ASC-H - atypical squamous cells, cannot exclude a high-grade squamous intraepithelial lesion. Intraepithelial refers to cells on the surface of the cervix. ASC-H cells do not appear normal, but doctors are uncertain about what the cell changes mean. However, there is a possibility that a pre-cancerous lesion is developing, so a colposcopy is recommended.
- LSIL - low-grade squamous intraepithelial lesion; this is the earliest pre-cancerous lesion. LSILs may be referred to as mild dysplasia or as cervical intraepithelial neoplasia type 1 (CIN-1). Although many LSIL lesions will resolve on their own, there is no way to predict which ones will resolve, so doctors will typically perform a colposcopy.
- HSIL - high-grade squamous intraepithelial lesion. HSILs are more abnormal-looking than LSILs and have a higher likelihood of progressing to cancer. HSILs include lesions that in other classification systems may be referred to as moderate or severe dysplasia, carcinoma in situ, and/or CIN-2 and CIN-3. A finding of HSIL necessitates a colposcopy.
- Squamous cell carcinoma is the most advanced category. This means that abnormal cervical squamous cells have invaded into the cervix. A finding of squamous cell carcinoma requires further testing and treatment. Keep in mind, when women undergo appropriate screening, most of the time, abnormalities in the cervix are detected and treated before they have had the chance to progress to cervical cancer.
Classification of Glandular Cells on the Pap Test
Glandular cells, which produce mucus, are found in the opening of the cervix and in the uterus. Abnormalities in these cells are more difficult to classify. Glandular cells that are seen on the Pap test most commonly come from the endocervix (area closest to the uterus). However, other glandular epithelial surfaces in the female reproductive tract may shed cells that are visible on the Pap test. Endometrial cells may also appear on Pap tests and reveal underlying abnormalities. Because the female reproductive tract is open to the abdominal cavity via the fallopian tubes, occasionally, cells from the ovary, fallopian tubes, peritoneum or other abdominal organs may be seen on the Pap smear. Glandular cells on the Pap test are classified as follows:
- Endometrial cells, cytologically benign, in a postmenopausal woman.
- Atypical glandular cells (AGC, formerly AGUS) that should be qualified further, if possible, as to whether a reactive or neoplastic process is favored. A finding of AGC will typically be followed by a colposcopy and possibly also endometrial sampling.
- Endocervical Adenocarcinoma.
- Endometrial Adenocarcinoma.
- Extrauterine Adenocarcinoma (e.g. ovarian, Fallopian tube, pancreas, etc.).
- Adenocarcinoma, not otherwise specified (i.e. unknown primary site).
HPV DNA TEST
The HPV test can be used for screening or as a next step after an abnormal pap test result. There are over 150 types of HPV, but only 14 types are thought to be "high-risk" for causing various types of cancer. Two of these types (16 & 18) are known to cause over 70% of cervical cancers. The HPV test looks for the highest risk types of HPV in the same sample used for the pap test. The results of the HPV test along with the pap test and your age and health will determine what the next steps will be.
Colposcopy: The next diagnostic step
An abnormal Pap smear result often requires further evaluation. If the abnormality is minor (i.e. inflammation, or HPV changes) your healthcare provider may choose to repeat the Pap test in a few months, as your own immune system may "clear" the HPV infection and a follow up Pap be normal. If the abnormalities have persisted or worsened, colposcopy is indicated. Colposcopy will enable your provider to make a more accurate diagnosis.
Colposcopy - A colposcope is a lighted microscope that is used to magnify the cervical tissue during a pelvic examination. The colposcope is used to visualize abnormal areas of the cervix and vagina that are too small to see with the naked eye. The entire transformation zone must be seen. The colposcopic examination is an office procedure and may be a bit more uncomfortable than a routine pelvic examination because of the pressure from the speculum lasting longer than a typical Pap test. The test takes 5 to 10 minutes to perform. During the examination, the examiner may take small samples of cervical tissue (biopsies), which are later examined by a pathologist. These diagnostic biopsies will guide further management.
From the examiner's perspective
From the patient's perspective
Treatment Options for Cervical Dysplasia
Cone Biopsy - A cone biopsy (also called cold knife cone biopsy) is a minor operation, which is usually performed in an outpatient surgical facility. In the operating room, the physician removes a small cone-shaped tissue sample from your inner cervix. This tissue is sent to a pathologist for detailed examination under a microscope. This procedure does not remove any of your reproductive organs and should have little impact on your future ability to become pregnant. If only dysplasia is found in the cone specimen, then often no additional treatment will be required. However, if invasive cancer is discovered, additional treatment (i.e. surgery or radiation therapy) is indicated. Therefore, a cone biopsy may be considered as therapeutic (if all of the dysplasia is removed) or diagnostic (if it discovers a worse problem that requires additional treatment).
Loop Electrosurgical Excision Procedure (LEEP) - The LEEP procedure is similar to a cone biopsy in that it removes a tissue sample from your cervix, which is then examined, under a microscope, by a pathologist. It may also be called an LLETZ (large loop excision of the transformational zone). The LEEP procedure uses a low voltage, electric wire to cut away the abnormal area and has the advantage of being easily performed in the office with local anesthesia. However, the LEEP procedure and cone biopsy are not equivalent and your physician will recommend which is the best option, depending on your case.
Cryosurgery - Cryosurgery is another treatment option that can be performed in the doctor's office. During the procedure, the doctor freezes and thereby destroys the dysplasia on your cervix. You may notice a brief unpleasant cold sensation during the freezing procedure. A disadvantage of cryosurgery is that no specimen is obtained for the pathologist to examine in order to exclude the possibility of invasive cancer.
If you have questions about your Pap test or the results of your test it is best to speak to your provider.
Association of Reproductive Health Professionals - "Understanding Cervical Cancer Screening Test Results"
World Health Organization. Human Papillomavirus and Cervical Cancer. 2019.
Wright T, Massad L, Dunton C, et al.2006 Consensus Guidelines for the Management of Women with Abnormal Cervical Cancer Screening Tests. American Journal of Obstetrics and Gynecology (2007;197(4):346-355).